Refine
Has Fulltext
- yes (53)
Is part of the Bibliography
- yes (53)
Year of publication
Document Type
Language
- English (53)
Keywords
- Toxikologie (32)
- Adenosine receptors (8)
- Adenosinrezeptor (5)
- Adenylate cyclase (4)
- G proteins (4)
- Pharmakologie (4)
- signal transduction (3)
- A1 adenosine receptors (2)
- Adenosin (2)
- G-protein (2)
- N-formyl peptides (2)
- Pharmazie (2)
- Radioligand binding (2)
- adenosine receptors (2)
- mast cells (2)
- membrane skeleton (2)
- (Rat brain membrane) (1)
- A(2B) receptors (1)
- A1 (1)
- A1 Adenosine receptors (1)
- A<sub>2</sub> Adenosine receptor (1)
- A\(_{2A}\) adenosine receptor antagonist (1)
- Adenosine receptor (1)
- Adenosine receptor antagonists (1)
- Atria (1)
- Barbiturat (1)
- Barbiturates (1)
- Chemotactic receptors (1)
- Cyclic AMP (1)
- Dermatologie (1)
- GABA-receptor complex (1)
- Human platelets (1)
- Immunologie (1)
- Ischemia/reperfusion (1)
- K + -channels (1)
- LTB4 receptor (1)
- Leukocyte/endothelium interaction (1)
- Lung (1)
- Mastzelle (1)
- Microcirculation (1)
- Molekularpharmakologie (1)
- N1E 115 cells (1)
- Niere (1)
- Phosphodiesterase (1)
- Photoaffinity labelling (1)
- Radiation inactivation (1)
- Radioligand binding - 86Rb + -efflux (1)
- Radioligands (1)
- Radioligauds (1)
- Ratte (1)
- Species differences (1)
- Target size (1)
- Theophylline (1)
- Venerologie (1)
- Xanthines (1)
- [3H]PIA binding (1)
- actin (1)
- adenosine (1)
- adenosine 3',5'-cyclic monophosphate (1)
- adenylate cyclase (1)
- agonists (1)
- antagonists (1)
- anti-Parkinson agents (1)
- anti-inflammatory agents (1)
- atopic eczema (1)
- barbiturates (1)
- binding affinity (1)
- brain membranes (1)
- calcium (1)
- chalcone (1)
- chemotactic receptors (1)
- chemotaxis (1)
- classification (1)
- coated vesicles (1)
- coumarin (1)
- cytoskeleton (1)
- desensitization (1)
- docking (1)
- drug (1)
- formyl peptides (1)
- gastrointestinal cancer (1)
- hA<sub>3</sub>AR (1)
- histamine release (1)
- human A(3) (1)
- human lung (1)
- indolylpyrimidylpiperazines (1)
- international union (1)
- molecular modeling (1)
- neurodegenerative diseases (1)
- neutrophils (1)
- partial agonists (1)
- phosphoinositides (1)
- photoaffinity labelling (1)
- potent (1)
- protein-coupled receptors (1)
- psoriasis (1)
- purine derivatives (1)
- radioligand (1)
- rat brain membranes (1)
- receptor binding (1)
- receptor solubilization (1)
- receptor-G protein coupling (1)
- receptor-G protein coupling. (1)
- receptors (1)
- solubilization (1)
- subtypes (1)
- targets (1)
- triazolotriazine derivatives (1)
Institute
- Institut für Pharmakologie und Toxikologie (53) (remove)
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by progressive loss of dopaminergic neurons in the substantia nigra of the human brain, leading to depletion of dopamine production. Dopamine replacement therapy remains the mainstay for attenuation of PD symptoms. Nonetheless, the potential benefit of current pharmacotherapies is mostly limited by adverse side effects, such as drug-induced dyskinesia, motor fluctuations and psychosis. Non-dopaminergic receptors, such as human A2A adenosine receptors, have emerged as important therapeutic targets in potentiating therapeutic effects and reducing the unwanted side effects. In this study, new chemical entities targeting both human A2A adenosine receptor and dopamine D2 receptor were designed and evaluated. Two computational methods, namely support vector machine (SVM) models and Tanimoto similarity-based clustering analysis, were integrated for the identification of compounds containing indole-piperazine-pyrimidine (IPP) scaffold. Subsequent synthesis and testing resulted in compounds 5 and 6, which acted as human A2A adenosine receptor binders in the radioligand competition assay (Ki = 8.7–11.2 μM) as well as human dopamine D2 receptor binders in the artificial cell membrane assay (EC50 = 22.5–40.2 μM). Moreover, compound 5 showed improvement in movement and mitigation of the loss of dopaminergic neurons in Drosophila models of PD. Furthermore, in vitro toxicity studies on compounds 5 and 6 did not reveal any mutagenicity (up to 100 μM), hepatotoxicity (up to 30 μM) or cardiotoxicity (up to 30 μM).